Skip to main content

Drug Interactions between digoxin and Robitet 500

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

tetracycline digoxin

Applies to: Robitet 500 (tetracycline) and digoxin

MONITOR CLOSELY: Tetracyclines may increase serum levels of orally administered digoxin by preventing specific bacteria, present in the lower intestine, from inactivating digoxin. About 10% of the population use this mechanism to metabolize digoxin. When digoxin was administered with tetracycline in a pharmacokinetic study done in adults, the digoxin serum concentration increased by 100%. Currently there is no data demonstrating the effects of other tetracyclines on digoxin levels. The risk of an interaction may be less with digoxin solution in capsules because absorption occurs in the upper GI tract.

MANAGEMENT: Close clinical monitoring of digoxin serum concentration as well as signs or symptoms of digoxin toxicity are recommended when antibiotic therapy is initiated or discontinued. It is advisable to obtain a baseline digoxin level prior to initiating concomitant therapy. Some authorities recommend reducing the digoxin dose by around 30% to 50% or modifying the dosing frequency, followed by additional monitoring. Patients should be advised to notify their physicians if they experience nausea, anorexia, fatigue, visual changes, slow pulse, and/or irregular heartbeats.

References

  1. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR "Inactivation of digoxin by the gut flora: reversal by antibiotic therapy." N Engl J Med 305 (1981): 789-94
  2. Lindenbaum J, Tse-Eng D, Butler VP, Rund DG "Urinary excretion of reduced metabolites of digoxin." Am J Med 71 (1981): 67-74
  3. Rodin SM, Johnson BF "Pharmacokinetic interactions with digoxin." Clin Pharmacokinet 15 (1988): 227-44
  4. "Product Information. Digoxin (digoxin)." Amneal Pharmaceuticals LLC (2019):
  5. "Product Information. PMS-Digoxin (digoxin)." Pharmascience Inc (2022):
  6. "Product Information. Digoxin (digoxin)." Aspen Pharma Trading Ltd (2022):
  7. "Product Information. Sigmaxin (digoxin)." Aspen Pharma Pty Ltd (2020):
  8. MacLeod-Glover N, Mink M, Yarema M, Chuang R "Digoxin toxicity: case for retiring its use in elderly patients?" Can Fam Physician 62 (2016): 223-8
  9. Zhanel GG, cheung d, Adam H, et al. "Review of eravacycline, a novel fluorocycline antibacterial agent." Drugs 76 (2016): 567-88
View all 9 references

Switch to consumer interaction data

Drug and food interactions

Moderate

tetracycline food

Applies to: Robitet 500 (tetracycline)

ADJUST DOSING INTERVAL: Administration with food, particularly dairy products, significantly reduces tetracycline absorption. The calcium content of these foods forms nonabsorbable chelates with tetracycline.

MANAGEMENT: Tetracycline should be administered one hour before or two hours after meals.

References

  1. "Product Information. Achromycin (tetracycline)." Lederle Laboratories PROD (2001):
  2. "Product Information. Declomycin (demeclocycline)." Lederle Laboratories PROD (2001):

Switch to consumer interaction data

Moderate

tetracycline food

Applies to: Robitet 500 (tetracycline)

GENERALLY AVOID: The bioavailability of oral tetracyclines and iron salts may be significantly decreased during concurrent administration. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the iron cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. In ten healthy volunteers, simultaneous oral administration of ferrous sulfate 200 mg and single doses of various tetracyclines (200 mg to 500 mg) resulted in reductions in the serum levels of methacycline and doxycycline by 80% to 90%, oxytetracycline by 50% to 60%, and tetracycline by 40% to 50%. In another study, 300 mg of ferrous sulfate reduced the absorption of tetracycline by 81% and that of minocycline by 77%. Conversely, the absorption of iron has been shown to be decreased by up to 78% in healthy subjects and up to 65% in patients with iron depletion when ferrous sulfate 250 mg was administered with tetracycline 500 mg. Available data suggest that administration of iron 3 hours before or 2 hours after a tetracycline largely prevents the interaction with most tetracyclines except doxycycline. Due to extensive enterohepatic cycling, iron binding may occur with doxycycline even when it is given parenterally. It has also been shown that when iron is administered up to 11 hours after doxycycline, serum concentrations of doxycycline may still be reduced by 20% to 45%.

MANAGEMENT: Coadministration of a tetracycline with any iron-containing product should be avoided if possible. Otherwise, patients should be advised to stagger the times of administration by at least three to four hours, although separating the doses may not prevent the interaction with doxycycline.

References

  1. Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54
  2. Gothoni G, Neuvonen PJ, Mattila M, Hackman R "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand 191 (1972): 409-11
  3. Venho VM, Salonen RO, Mattila MJ "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol 14 (1978): 277-80
  4. "Product Information. Minocin (minocycline)." Lederle Laboratories PROD (2002):
  5. Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5
  6. Bateman FJ "Effects of tetracyclines." Br Med J 4 (1970): 802
  7. Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K "Interference of iron with the absorption of tetracyclines in man." Br Med J 4 (1970): 532-4
  8. Greenberger NJ "Absorption of tetracyclines: interference by iron." Ann Intern Med 74 (1971): 792-3
  9. Neuvonen PJ, Penttila O "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol 7 (1974): 361-3
  10. "Product Information. Seysara (sarecycline)." Allergan Inc (2018):
  11. "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc. (2018):
View all 11 references

Switch to consumer interaction data

Minor

digoxin food

Applies to: digoxin

Administration of digoxin with a high-fiber meal has been shown to decrease its bioavailability by almost 20%. Fiber can sequester up to 45% of the drug when given orally. Patients should be advised to maintain a regular diet without significant fluctuation in fiber intake while digoxin is being titrated.

Grapefruit juice may modestly increase the plasma concentrations of digoxin. The mechanism is increased absorption of digoxin due to mild inhibition of intestinal P-glycoprotein by certain compounds present in grapefruits. In 12 healthy volunteers, administration of grapefruit juice with and 30 minutes before, as well as 3.5, 7.5, and 11.5 hours after a single digoxin dose (0.5 mg) increased the mean area under the plasma concentration-time curve (AUC) of digoxin by just 9% compared to administration with water. Moreover, P-glycoprotein genetic polymorphism does not appear to influence the magnitude of the effects of grapefruit juice on digoxin. Thus, the interaction is unlikely to be of clinical significance.

References

  1. Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54
  2. Becquemont L, Verstuyft C, Kerb R, et al. "Effect of grapefruit juice on digoxin pharmacokinetics in humans." Clin Pharmacol Ther 70 (2001): 311-6

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.